Quinine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Quinine
Quinine: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Quinine, so there is currently no new predicted indication. The drug’s own recorded uses are listed below. They come from existing records, not from model predictions.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 2 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| malaria |
| plasmodium falciparum malaria |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 1975Y | Quinate | Tablet containing quinine sulfate dihydr | Valid |
Safety Considerations
- Contraindications (from TxGNN model (deep learning) output, not label text): long QT syndrome (including familial), torsades de pointes, atrial fibrillation and flutter, liver disease, gallbladder disease, thrombocytopenia and thrombocytopenic purpura, haemolytic-uraemic syndrome, myasthenia gravis and other neuromuscular junction disease, hypoglycaemia, chronic kidney disease and end-stage renal failure, optic neuritis, and blackwater fever. These come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
- Drug Interactions: 100 interactions were identified. Those rated Major include loperamide, clarithromycin, dolasetron, picosulfuric acid, sodium sulfate, and polyethylene glycol (3350 with electrolytes). Examples rated Moderate include famotidine, aprepitant, dexamethasone, bisacodyl, palonosetron, and several antidiabetic agents (chlorpropamide, glimepiride, insulins). Many of the major interactions relate to QT prolongation or electrolyte disturbance.
- Other considerations: Quinine’s known hyponatraemia and renal adverse-event profile argues for caution in the lower-ranked renal predictions.
Please also refer to the TGA-approved Product Information (PI) for full warnings and precautions.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.